Funding accelerates R&D and retail expansion as Bird&Be fills gaps in fertility care.

TORONTO, Sept. 22, 2026 — Bird&Be, the fertility and wellness brand making supplements and at-home tests for women and men at every stage of the fertility journey, today announced $13M in funding to fuel product development, retail expansion, and access to trusted, evidence-based reproductive health support – whether someone is trying to conceive, managing a condition like PMOS, supporting a pregnancy, or simply taking a proactive first step in understanding their fertility. The round is led by BDC Thrive, BFG Partners, and supported by BAM Ventures, Founder Collective, Rejuvenation Ventures, and HSR Ventures.

Why the fertility category needs a trusted intervention:

• 1 in 6 people experience infertility, and up to 50% of cases involve male factors; yet fewer than 1,400 fertility specialists (REIs) practice nationwide, and nearly half of U.S. counties lack an OB-GYN.
• PMOS affects 1 in 10 women but can take many years to diagnose, leaving an estimated 70% of women undiagnosed and unsupported in managing their cycles and fertility.
• Prenatal vitamins need a higher standard too: a recent Consumer Reports investigation found nearly all (15 of 17) prenatal vitamins tested contained more or less of key nutrients than their labels claimed, including folic acid, which is essential for neural tube development. Bird&Be’s Prenatal met all of its label claims in Consumer Reports’ evaluation. Note: Consumer Reports does not endorse products or services.

With third-party-tested supplements formulated and backed by OB-GYNS, REIs, and naturopathic fertility specialists, Bird&Be steps in to give women and men the nutritional support they need for healthy conception, pregnancies, and postpartum recovery. They are also the only brand to offer at-home diagnostic tests alongside supplements –  Sperm Test Kits and Ovarian Reserve Screening Tests for under $100 – giving couples the tools to take proactive care of their reproductive health to improve outcomes.

In its first three years, Bird&Be grew to an eight-figure brand with nearly 100% year-over-year growth and 75% of revenue coming from subscriptions. The brand has grown its clinician-referral channel 200% year-over-year — with more than 10% of customers now coming through a healthcare provider recommendation. Bird&Be launched in 300 Ulta Beauty stores in September 2025 and expanded to nearly 1,000 stores by spring 2026, becoming the first fertility brand to place male and female products side by side in a national beauty retailer. Bird&Be recently partnered with Mandell’s Clinical Pharmacy to extend its reach directly to patients navigating fertility treatment in all 50 states.

The new funding will fuel research and clinical studies, product development, continued retail expansion, and the growth of Bird&Be’s clinical distribution channel.

“We started Bird&Be because my Co-Founder Breanna Hughes and I didn’t have the support we needed navigating PMOS and pregnancy loss ourselves,” said Samantha Diamond, Bird&Be Co-Founder and CEO. “We get it because we lived it. Every product we make helps our customers and community feel educated and in control. We intentionally created a brand that would bring men into the fertility narrative as well, giving them the supplements and tools to care for their own reproductive health and grow their families. We’ve been able to support hundreds of thousands of people in their fertility journeys over the past few years and the new funding helps us make trusted products even more accessible when and where people need care most.”

“Bird&Be is building a category-defining company at the intersection of women’s health, consumer health, and preventative care,” said Mona Minhas, Managing Partner, BDC Thrive Venture Fund. “By combining science-backed products with accessible education, Bird&Be is addressing a significant unmet need in a large and underserved market. We’re excited to lead this investment and partner with the team as they scale their impact. Supporting exceptional women-led companies like Bird&Be is central to Thrive’s mandate and to BDC’s commitment to fueling innovation and economic growth in Canada.”

“Bird&Be pairs a deep body of fertility science with a product experience people actually stick with. That combination is rare,” said Elizabeth Earle, Vice President at BFG. “BFG strongly believes that brands built on real transparency, like Bird&Be, should be within reach of more people and we’re eager to support Samantha and Breanna’s mission in bringing them to women and men hoping to build their families.”

About Bird&Be

Bird&Be is a fertility and wellness brand providing supplements and at-home tests for both partners at every stage of the fertility journey. Formulated by fertility doctors, OB-GYNs, and naturopathic specialists, Bird&Be offers prenatal, pregnancy, postpartum, and hormone-supporting supplements with therapeutic, bioavailable, third-party-tested ingredients. Bird&Be products are available on birdandbe.com, in Ulta stores and online, and through clinical partnerships like Mandell’s Clinical Pharmacy. Learn more at birdandbe.com 

SOURCE Bird&Be

SAN DIEGO, Sept. 22, 2026 — Primrose Bio, Inc. (“Primrose”), a provider of production solutions for next-generation biologics, today announced the closing of a financing round led by new investor Signet Healthcare Partners (“Signet”), with significant participation from existing investors 1315 Capital, Ligand Pharmaceuticals Incorporated (Nasdaq: LGND), LDV Partners, and Agent Capital. In conjunction with the financing, James Gale, Founding Partner and Managing Director of Signet, has joined Primrose’s Board of Directors.

The proceeds will help Primrose continue to expand the reach and capabilities of its differentiated technology portfolio:

• Pfenex Expression Technology^® (“Pfenex”), a scalable microbial expression platform for efficient, high-yield production of complex, engineered proteins used in six approved biologics
• Prima RNApols^®, proprietary RNA polymerases for consistent, scalable, high-quality mRNA manufacturing (available in RUO- and GMP-grade)
• PeliCRM197^®, a validated carrier protein used in multiple approved vaccines (RUO and GMP) 

“This financing marks an important next step for Primrose and reflects confidence in our technologies, team and commercial opportunity,” said Andrew Burch, Chief Executive Officer of Primrose Bio. “As the engineering of biologic and nucleic acid medicines advances, developers need more robust production systems that also improve quality, yield, speed, scalability and cost. This capital will help us broaden adoption, enhance capabilities and accelerate customers moving therapeutic and vaccine programs forward toward clinical trials.” 

“Signet sees a compelling opportunity across Primrose’s portfolio,” said James Gale. “Having partnered with The Dow Chemical Company to establish Pfenex Inc. in 2009, we have seen the platform’s commercial value firsthand. Primrose is building on that foundation with further advances in Pfenex technology as well as Prima RNApols and PeliCRM197. We are pleased to invest in this next phase of growth and support the team as they scale the business and help more customers improve manufacturing performance across multiple therapeutic modalities.”

About Primrose Bio, Inc.

Primrose Bio develops and commercializes manufacturing technologies that close gaps in biologics, mRNA and vaccine production. Primrose’s major offerings include Pfenex Expression Technology^®: a proprietary microbial production system used in six approved products with up to 20x higher yields and a strong record across diverse protein modalities; Prima RNApols^®: improved enzymes for mRNA manufacturing; and PeliCRM197^®: a commercially validated CRM197 carrier protein used for conjugate vaccines.  Several of the world’s leading pharmaceutical companies use Primrose’s technologies in marketed products, including Merck, Jazz Pharmaceuticals, Alvogen, and Serum Institute of India. For more information, please visit: www.primrosebio.com.

About Signet Healthcare Partners

Signet Healthcare Partners is a healthcare growth equity firm that invests in commercial-stage pharmaceutical (pharma services and therapeutics) and medical technology companies. Founded in 1998 and based in New York, Signet has invested in more than 60 companies, supporting entrepreneurs with capital, strategic guidance, and deep industry networks. For more information, please visit: www.signethealthcarepartners.com.

SOURCE Primrose Bio

Left Lane Capital incubated and led the round as Rising Tide scales property management firms with shared technology and capital, without asking them to give up their name, team, or local relationships

CHICAGO, Sept. 22, 2026 — Rising Tide, which acquires and invests in independently owned residential property management companies, today announced the close of an undisclosed seed round led by Left Lane Capital. Left Lane incubated the company alongside CEO Blake Mohseni on a shared conviction: property management is a large and deeply fragmented market; it is mission-critical to the lives of everyday consumers, and its complexity across multiple stakeholders creates unique opportunities for AI to improve the customer experience.

Property management is a $100B+ market split across more than 240,000 property management firms that together handle a large share of residential rentals. Most run without the technology, systems, and back-office support that larger, well-capitalized platforms take for granted. The result: owners spend more time on manual admin than on building the tenant and owner relationships that actually differentiate a good property manager. Many also face a tough choice when it comes time to sell or transition: sell to a private equity firm that rebrands them under a national name, or figure out succession alone.

“AI is changing the definition of what premier service looks like in property management. It gives our operators more room for the relationships with owners and tenants that actually built their business,” said Blake Mohseni, Founder and CEO of Rising Tide. “This funding brings that same approach to more independent property management firms: real technology, real capital, and partnership instead of a takeover.”

Rising Tide takes a different approach: a federation of independent property management companies. Each one gets shared technology and capital to grow, while the local brand, the team, and the relationships an owner spent years building remain exactly as they are.

There’s no shortage of AI hype in property management right now. The hard part is knowing how to actually put it to work. That’s where Rising Tide comes in, through The Lab, where the company builds and tests its AI tools inside real property management businesses through hands-on implementation at no cost. The Lab is live today with three property management firms. Rising Tide keeps ownership of what it builds; the operators get full use of it for free, and their business data never leaves their hands.

Vinny Pujji, Co-founder and Managing Partner of Left Lane Capital, said, “We have invested over $100 million into AI companies transforming traditional services industries, from accounting to dental. Property management is universal, mission-critical, and not for the faint of heart. Blake and his team have the thoughtful approach needed to bring AI to the industry and drive modernization alongside tenured operators.”

About Rising Tide

Rising Tide is building a federation of independent property management companies with real capital and technology behind each one, while the local brand, team, and relationships are fully intact. Learn more at www.risingtidehq.com.

About Left Lane Capital

Founded in 2019, Left Lane Capital is a New York and London based venture capital and growth equity firm investing in high growth internet and consumer technology businesses globally. Left Lane’s mission is to partner with extraordinary entrepreneurs who create category defining companies across growth sectors of the economy. For more information, visit www.leftlane.com.

SOURCE Rising Tide

Round Led by .406 Ventures Fuels Teal Health’s Next Phase of Growth, Expanding Payor, Health System, Employer and Provider Partnerships Ahead of Broad Insurance Coverage in 2027

SAN FRANCISCO, Sept. 22, 2026 — Teal Health, creators of the Teal Wand™, the first and most accurate FDA-authorized self-collection device for at-home HPV cervical cancer screening, today announced $22 million in Series A funding to meet accelerating consumer demand and expand access ahead of broad insurance coverage beginning in January 2027.

The round was led by .406 Ventures, with continued backing from Emerson Collective (managed by Yosemite), Forerunner, and Serena Ventures, and new participation from Japan-based MPower Partners. The financing brings Teal Health’s total funding to $45 million. It arrives at a critical moment where nearly one in three U.S. women isn’t up to date on screening, largely due to physician shortages causing limited appointment availability and therefore making the traditional in-office screening difficult to access. Increasing preventive care options for women is a national imperative. As the first to deliver an accurate, convenient at-home screening alternative, Teal is already defining the future of women’s preventive health, ahead of January 2027 federal guidelines that will require most health plans to cover self-collection for cervical cancer screening.

The new capital will fuel a growing network of payor, health system, employer, provider, and brand partnerships that make screening available wherever women receive care, access benefits, or make decisions about their health. Teal Health is also expanding direct-purchase options for individuals and organizations. Together, these channels are designed to move at-home screening beyond early adoption and establish it as a routine, widely available, and highly preferred part of preventive care nationwide. The funding will also support continued hiring across key clinical, commercial, technology, and operational functions as Teal scales to serve more women and partners.

“We designed Teal for all women, whether they are behind on their screening or coming due. Screening is just too difficult today, whether that is finding an appointment, the time in your day to attend, or the physical discomfort. Women need an accurate, trusted alternative that makes it easy to screen,” said Kara Egan, CEO and Co-Founder of Teal Health. “This funding allows us to scale to meet the demand of patients and providers. It’s clear this option is preferred by women and now we can ensure everyone has a way to stay healthy.”

The Teal Wand is the first FDA-authorized self-collection device for at-home HPV cervical cancer screening – no speculum or in-office visit required. Teal Health pairs a private, speculum-free at-home sample collection with a telehealth visit, delivers results through a secure platform, and connects patients to follow-up care when it’s needed. Women love having this option, and Teal data shows 59% of women who choose Teal are underscreened; these are women who now have an option to take care of their health. Thousands of women have rated the end-to-end experience an average of 4.95 out of 5, clear evidence that this is the kind of screening experience women have been waiting for.

“Patients are demanding more convenient ways to access healthcare, and Teal has proven that convenience doesn’t have to come at the expense of accuracy,” said Kathryn Taylor Reddy, Partner at .406 Ventures. “With insurance coverage expanding in 2027, Teal Health is positioned to transform how millions of women receive essential preventive healthcare.”

Since receiving FDA-authorization in 2025, Teal Health has already screened thousands of women nationally, been incorporated in national screening guidelines, advanced research on self-collection screening with 17 peer-reviewed papers and presentations, and is partnering with health systems, providers, employers, and payers – providing access to the Teal Wand where women already receive care – closing screening gaps, easing the load on clinics, and reaching the women who are overdue. Cervical cancer is one of the most preventable cancers, yet thousands of women in the U.S. are diagnosed each year – and roughly 4,320 will die from it this year. This funding extends these partnerships and opens new ways for organizations and individuals to offer screening directly, pushing at-home screening from early-adopter territory into routine care.

To learn more, visit www.getteal.com.

About Teal Health

Teal Health is a women’s health company on a mission to eliminate cervical cancer by making screening accessible, comfortable, and accurate. Its flagship product, the Teal Wand, is the first FDA-authorized at-home HPV self-collection device for cervical cancer screening. Through its telehealth platform, Teal Health provides an end-to-end screening experience that includes access to providers, at-home sample collection, secure results, and support with follow up care. As a member of the Cervical Cancer Roundtable (a collaboration between the American Cancer Society and Cancer Moonshot), Teal Health is helping to shape the future of preventive care. The company continuously advances screening standards through robust clinical evidence, including 17 peer-reviewed papers and presentations. Learn more at getteal.com.

SOURCE Teal Health

Strong participation from existing shareholders and strategic investors drives raise beyond the $10 million target

SCOTTSDALE, Ariz., Sept. 22, 2026 — Monetary Metals®, the global Gold Yield Marketplace^® platform, raised $10.5 million through its latest equity financing, surpassing the initial $10 million target.

The new capital will support the continued development of the Monetary Metals Gold Yield Marketplace®. The company is on an exponential growth trajectory, having more than doubled the amount of gold deployed year over year, and was recently named to the top 8% of the prestigious 2026 Inc. 5000 list.

Founded in 2012 by economist and entrepreneur Keith Weiner, Monetary Metals enables gold owners to earn a yield on their gold, challenging the traditional view that gold is an unproductive asset. The yield is achieved by leasing gold to precious metals businesses such as jewelers and refiners, to finance their gold inventory.

This equity raise includes investment from both existing and new shareholders. The latest financing brings the total amount raised by Monetary Metals to nearly $25 million.

Keith Weiner, founder and CEO of Monetary Metals said: 

“The continued support we receive from investors reflects growing recognition that we have not only created a new category of gold ownership—gold fixed income—but that we are the leader in that category. Because of Monetary Metals, gold is a productive, income-generating asset for clients across the globe. We are seeing strong growth across both sides of our marketplace, from gold owners seeking gold-denominated yield to precious metals businesses accessing more efficient financing solutions than those offered by traditional banks. We are grateful to our investors for supporting our vision of unlocking the productivity of gold and for their continued confidence in our mission as we scale the platform and expand its reach.”

Media Contacts:

About Monetary Metals:

Monetary Metals® is Unlocking the Productivity of Gold™ by offering a Yield on Gold, Paid in Gold® to investors, and Gold Financing, Simplified™ to gold-using businesses (mints, miners, refiners, jewelers, etc.).

Since 2016, individuals and institutions around the world have been earning a yield in gold and silver every month through our Gold Yield Marketplace®.

SOURCE Monetary Metals & Co.

Atum raises $13.5m to build the world’s first open payments network.

SAN FRANCISCO, Sept. 22, 2026 — Atum today emerged from stealth having built the open payments network, a first of its kind, for global money movement. Atum connects payment companies, developers, and enterprises through a single coordination layer, without issuing a currency, operating a blockchain, favoring a rail, or taking custody of customer funds. The company is launching with $13.5 million of funding from Variant, PayPal Ventures, Abstract Ventures, Road Capital, Mirana Ventures, First Commit, Credibly Neutral, and strategic advisor Charlie Songhurst.

Payments are fragmented across currencies, chains, apps, and local rails that do not interoperate, and every handoff adds cost, delay, and complexity. Stablecoins offer fast, low-cost global rails, but are spread across many blockchains, which pushes that complexity onto users. Atum is the coordination layer between them. Any integrator, developer, or application can submit a payment request, while settlement providers compete to fulfill the payments across any supported chain and stablecoin, with native authorization, reversible payments, and identity. Senders specify what they will send; receivers get what they asked to receive.

Atum is incentivized only by volume, and connects participants through a marketplace where settlement providers compete to fulfill each payment. That structure is what makes the network credibly neutral: its interests are aligned with everyone building on it. It is an open-loop payments and commerce platform.

The network serves businesses moving money: card issuers and acquirers, payment service providers, card networks, stablecoin orchestrators, wallets, fintechs, and enterprises—plus developers building on top. Atum supports financial institutions and stablecoin card issuers, for both non-agentic stablecoin payments and agentic payments through agentic protocols including x402 and MPP. Both humans and agents are completing payments on Atum today.

“This is my life’s work,” said Pete Cooling, founder and CEO of Atum. “In 2014 I saw that blockchains were payments networks, and everything since has pointed to the same conclusion. Onchain accounts are the future bank accounts, and new infrastructure is needed to make money move more seamlessly than it does today. Atum is that infrastructure.”

Cooling formerly led the crypto product team at Visa and has been researching and building blockchain-based payments systems over the past decade. He served as Visa’s representative on Linux’s OpenWallet Foundation, helping guide standards for digital wallets across identity, financial accounts, payment cards, and stablecoins.

Atum is open to builders today in at atum.xyz

About Atum

Atum is the open payments network for global money movement. Atum connects payment companies, developers, and enterprises through a unified coordination layer that handles authorization, routing, and confirmation without being a counterparty and without taking custody. Atum issues no currency, runs no blockchain, favors no rail, and doesn’t compete with any participant on its network. Learn more at atum.xyz.

Media Contact: Amy Van Aarle, 1-617-935-5837, [email protected] 

SOURCE Atum

BOSTON, Sept. 22, 2026 — Creatio, an AI CRM and workflow platform where people and AI agents work together, today announced a $300 million investment from 2026 through 2028 in Creatio Bank.AI, its market-leading offering for banks and financial institutions.

The investment comes as financial institutions rapidly accelerate their adoption of AI, and demand for Creatio’s platform continues to grow — Creatio’s financial services vertical grew 48% YoY. The $300 million commitment will build on this momentum, accelerating product AI innovation while expanding the enablement and deployment capabilities, and partner ecosystem needed to drive AI adoption at scale across financial institutions.

With deep experience in financial services, Creatio has built long-standing relationships with leading organizations including Nasdaq, First National Bank of Pennsylvania, Metro Bank, MetLife, CEC Bank, OTP Bank, National Bank of Panama, ESL Credit Union, and many others.

“The next generation of banking will be built around people and AI agents working together across customer and operational workflows,” said Katherine Kostereva, CEO of Creatio. “Our $300 million investment in Creatio Bank.AI will accelerate this transition, giving financial institutions the technology, industry expertise, and partner ecosystem to adopt AI faster and at enterprise scale.”

$300 Million Investment to Accelerate Innovation and Adoption
Between now and 2028, Creatio will significantly increase investment across the following strategic areas:

1. Product and AI innovation
Creatio will further accelerate the development of its Creatio Bank.AI platform, combining the market-leading AI platform, best-in-class AI CRM, and pre-built banking agents.

The platform powers three core banking domains: Growth, Service, and Operations. Growth agents accelerate customer acquisition, onboarding, and share-of-wallet expansion. Service agents elevate customer experience with faster, more personalized resolution. Operations agents streamline compliance, regulatory reporting, and mid- and back-office work.

Creatio will continue to advance its already superior AI Studio, enhancing no-code designers for both personal and enterprise AI agents, centralized AI governance, integrations, AI modality management, security, and enterprise-grade observability.

2. AI adoption and enablement
Creatio is reinforcing its investment in AI adoption and enablement for customers and partners. The focus is on equipping the banking community with the knowledge, frameworks, and hands-on guidance to adopt AI at scale.

The investment expands AI activation programs for customers and partners: dedicated training programs, AI accelerator workshops, and industry-specific guidance. Creatio is also strengthening its global channel delivery capabilities, arming implementation partners with the expertise to help financial institutions deploy high-value AI use cases.

Removing the Limits to AI Adoption in Banking
The investment builds on Creatio’s Unlimited Enterprise vision, enabling people and AI agents to work together on a single platform without traditional constraints around users, agents, workflows, applications, or scale.

As part of this broader commitment to the banking community, Creatio recently launched the Bank.AI hub, a dedicated destination for financial services executives to navigate the AI era. On September 24, Creatio will also host “Bank.AI: Practical AI Use Cases for Banking” digital event, and on October 27, the Bank.AI Summit in Chicago, bringing together industry leaders to share best practices for AI adoption and transformation.

About Creatio

Creatio is an AI CRM and workflow platform where people and AI agents work together — with no limits on users, agents, or scale. We help midsize and large organizations run customer workflows in the AI era. Headquartered in Boston, MA, with a global team and a large ecosystem of partners, Creatio serves thousands of customers in over 100 countries and automates tens of millions of workflows daily. Genuine care for our clients and partners is at the heart of our DNA.

Media Contact
Judyta Krylova
+1 617 765 7997
[email protected]

SOURCE Creatio

SAN FRANCISCO, Sept. 22, 2026 — Superpower today announced a new partnership with Sequoia to bring a more proactive model of preventive health to employers and their teams. The partnership will begin with Sequoia’s own 800+ employee workforce, giving Sequoia firsthand experience with Superpower while simultaneously making the solution available to eligible client organizations across its employer ecosystem.

Employer healthcare often starts after something has already gone wrong. Symptoms appear. A diagnosis is made. Risk shows up as a claim. Superpower is working to shift that experience earlier, helping people better understand their health before issues become more serious and helping employers support preventive care in a more meaningful way.

The partnership with Sequoia is designed to make that model easier for employers to evaluate and adopt. Sequoia works with more than 2,500 companies and reaches more than 600,000 people, giving it a broad view into the challenges employers face as they manage rising healthcare costs, fragmented benefits, and growing demand for more personalized employee support.

Many people want to be more proactive about their health, but the current system can make that difficult. Annual visits often rely on limited testing and provide only a snapshot in time. Health records may be spread across providers, apps, and systems. New technology can make guidance more personalized, but it works best when connected to comprehensive data and clinical support.

Superpower turns a simple blood draw into an ongoing preventive health experience. Members receive 150+ biomarker testing at home, at thousands of lab locations, or onsite. They also receive a longitudinal health profile that can combine labs, health records, and wearable data, along with a personalized action plan, 24/7 Health AI, licensed clinical support, proactive outreach, and retesting to track progress over time. When the data points to care or a benefit an employer already offers, Superpower helps the member understand where to go next.

By partnering with Sequoia, Superpower can bring this experience to an employer audience that is actively looking for more proactive, integrated ways to support workforce health. Sequoia will begin by offering Superpower to its own employees, then use that experience to advise eligible clients that are evaluating comprehensive preventive health as part of their broader benefits strategy.

“Most people are trying to make health decisions with limited information and a fragmented view of their health. Superpower brings together comprehensive testing, technology, and clinical support so people can better understand what is happening in their bodies and take action earlier. Partnering with Sequoia helps us bring that model to employers in a thoughtful, credible way, starting with Sequoia’s own team,” said Max Marchione, Chief Executive Officer at Superpower.

Sequoia’s decision to begin with its own workforce reflects the way many employers are approaching new health solutions: they want to understand the employee experience, the operational requirements, and the potential value before recommending or scaling them more broadly.

“Employers have made significant investments in healthcare, but much of that support begins after a condition is already known. We see an opportunity to help people engage earlier, with better information and clearer next steps. By offering this to our own team, we can learn firsthand what this experience delivers and help clients evaluate whether it fits into their broader preventive health strategy,” said Christina Sullivan, Chief Client Officer at Sequoia.

Health costs continue to rise, and employers often have limited visibility into health risks before they become more serious and more expensive. Through this partnership, Superpower and Sequoia aim to help employers move upstream, supporting people earlier, connecting them with appropriate care, and making better use of the benefits already available to them.

Eligible Sequoia client organizations should reach out to their Sequoia representative for more information.

About Superpower

Superpower has quickly become one of the most trusted names in preventive healthcare. The company has raised more than $40 million in funding, with its Series A led by Forerunner Ventures. Its membership combines comprehensive lab testing across 150+ biomarkers, AI-powered insights, personalized protocols, and 24/7 access to a clinical care team. The platform brings together each member’s test results with their broader health context – including previous labs, real-time wearable data, family history, and conversations with Superpower AI – to uncover trends, surface potential risks, and deliver ongoing guidance that evolves alongside them. For further information, visit www.superpower.com.

About Sequoia

Sequoia is the strategic partner helping investor-backed companies of all sizes achieve their business goals through smarter people spend. For over 25 years, we’ve guided the most innovative employers to navigate growth and get the most out of their global people investment. With our expert advisory team and integrated platform, we help clients drive business impact through their total comp and benefits, improving executive decision making, controlling costs, protecting the business, and elevating the employee experience. Visit Sequoia.com or follow us on LinkedIn to learn more.

SOURCE Superpower

Appointment strengthens Grafine’s leadership team and supports the firm’s continued growth and commitment to investors

NEW YORK, Sept. 22, 2026 — Grafine Partners, a principal investment firm focused on generating alpha in the lower middle and middle market, today announced that Suzanne Flannery has joined the firm as Managing Director, Head of Strategic Initiatives. In this newly created role, Ms. Flannery will work across the investment, capital formation and operations teams to further institutionalize Grafine as it continues to attract capital from sophisticated global investors and increase its direct investment activity.

Since founding Grafine in 2019, Founder and Managing Partner Elizabeth Weymouth has built a distinctive investment firm around seeking to identify exceptional sector-specialist private equity investors launching new firms and investing alongside them in high-alpha opportunities.

“We are delighted to welcome Suzanne to Grafine,” said Ms. Weymouth. “She brings a unique and valuable combination of investment experience, strategic perspective, and operating discipline to our growing platform. Her experience will strengthen our ability to serve our investors as we grow, helping us scale thoughtfully while continuing to provide the performance and high level of engagement that are central to Grafine.”

Ms. Flannery brings more than two decades of experience spanning alternative investments, business strategy and institutional asset management. Most recently, she served as Managing Director and Head of Product Marketing Platform at Neuberger Berman, where she led a global team supporting the firm’s investment offerings. Previously, she spent nine years at Goldman Sachs in senior roles across portfolio management, client solutions and hedge fund investing. Earlier in her career, she worked at J.P. Morgan and Monitor Group.

Ms. Flannery holds an MBA from Harvard Business School and an Honors Business Administration degree from Ivey Business School at Western University.

About Grafine Partners

Grafine Partners is a principal investment firm focused on generating alpha in the lower middle and middle market – segments offering some of private equity’s most compelling risk-adjusted return opportunities. The firm pursues this opportunity by partnering with sector-specialist investors launching new firms whose proprietary deal flow, deep domain expertise, and demonstrated track records of outperformance create what Grafine believes is a differentiated and repeatable sourcing advantage.  

Zach Kouwe
Dukas Linden Public Relations
[email protected] 

SOURCE Grafine Partners